News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim GmbH Release: AF Patients Who Require Surgery Benefit From a Shorter Treatment Interruption on Dabigatran Etexilate (Pradaxa®) Compared to Warfarin


6/18/2012 10:21:41 AM

INGELHEIM, Germany--(BUSINESS WIRE)--For Non-US, Non-UK & Non-Canadian Media Only: Findings published in Circulation demonstrate that Pradaxa® (dabigatran etexilate) is associated with a substantially shorter interruption of oral anticoagulation therapy compared to warfarin in patients with atrial fibrillation (AF)1 who require surgery, allowing patients to undergo procedures more quickly and reducing the time of reduced protection against stroke. Additionally, the study found that discontinuing Pradaxa® within 48 hours of surgery was associated with a lower risk of peri-operative bleeding compared to similar discontinuation times with warfarin.1

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES